MARKET

FENC

FENC

Fennec Pharmaceuticals Inc
NASDAQ
7.66
-0.05
-0.58%
Opening 15:09 01/02 EST
OPEN
7.74
PREV CLOSE
7.70
HIGH
7.74
LOW
7.41
VOLUME
107.47K
TURNOVER
--
52 WEEK HIGH
9.92
52 WEEK LOW
4.680
MARKET CAP
261.45M
P/E (TTM)
-30.3409
1D
5D
1M
3M
1Y
5Y
1D
Major Investor Makes a Bold Exit Move in Fennec Pharmaceuticals
TipRanks · 12/30/2025 02:01
Southpoint Capital Advisors Reports Sale of Fennec Pharmaceuticals Common Shares
Reuters · 12/29/2025 21:35
Weekly Report: what happened at FENC last week (1222-1226)?
Weekly Report · 12/29/2025 09:16
Southpoint sells $7.5M worth stock of Fennec Pharmaceuticals
Seeking Alpha · 12/29/2025 05:12
Southpoint Trims Stake in Fennec Pharmaceuticals to 8%
TipRanks · 12/26/2025 23:02
SOUTHPOINT CAPITAL ADVISORS- SOUTHPOINT CONTROLS 2.7 MLN COMMON SHARES, 8% OF OUTSTANDING COMMON SHARES OF FENNEC
Reuters · 12/26/2025 22:46
Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)
Barchart · 12/26/2025 16:44
Weekly Report: what happened at FENC last week (1215-1219)?
Weekly Report · 12/22/2025 09:16
More
About FENC
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

Webull offers Fennec Pharmaceuticals Inc stock information, including NASDAQ: FENC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FENC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FENC stock methods without spending real money on the virtual paper trading platform.